To determine if a “whole practice” educational intervention improves the assessment of patients with shingles within 72 hours of onset of rash, and hence recruitment into the host trial: ATHENA (AmiTriptyline for the prevention of post-HErpetic NeuralgiA).
Trial Forge will make trials more efficient by looking for marginal gains across all trial processes, from research question to implementation into routine care. It will encourage everyone connected with trials to be more sceptical of what we do by asking for the evidence behind all of our trial decisions.